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Abstract
Background: Acute myelogenous leukemia (AML) progresses uniquely in each patient. However, patients are
typically treated with the same types of chemotherapy, despite biological differences that lead to differential
responses to treatment.
Results: Here we present a multi-lineage multi-compartment model of the hematopoietic system that captures
patient-to-patient variation in both the concentration and rates of change of hematopoietic cell populations. By
constraining the model against clinical hematopoietic cell recovery data derived from patients who have received
induction chemotherapy, we identified trends for parameters that must be met by the model; for example, the mitosis
rates and the probability of self-renewal of progenitor cells are inversely related. Within the data-consistent models,
we found 22,796 parameter sets that meet chemotherapy response criteria. Simulations of these parameter sets
display diverse dynamics in the cell populations. To identify large trends in these model outputs, we clustered the
simulated cell population dynamics using k-means clustering and identified thirteen ‘representative patient’
dynamics. In each of these patient clusters, we simulated AML and found that clusters with the greatest mitotic
capacity experience clinical cancer outcomes more likely to lead to shorter survival times. Conversely, other
parameters, including lower death rates or mobilization rates, did not correlate with survival times.
Conclusions: Using the multi-lineage model of hematopoiesis, we have identified several key features that
determine leukocyte homeostasis, including self-renewal probabilities and mitosis rates, but not mobilization rates.
Other influential parameters that regulate AMLmodel behavior are responses to cytokines/growth factors produced in
peripheral blood that target the probability of self-renewal of neutrophil progenitors. Finally, our model predicts that
the mitosis rate of cancer is the most predictive parameter for survival time, followed closely by parameters that affect
the self-renewal of cancer stem cells; most current therapies target mitosis rate, but based on our results, we propose
that additional therapeutic targeting of self-renewal of cancer stem cells will lead to even higher survival rates.
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Background
Acute myelogenous leukemia (AML) is a cancer of the
white blood cells stemming from the myeloid lineage that
produces cells including neutrophils and monocytes [1].
On average, four in 100,000 individuals will develop AML,
with a median age of 67 years at diagnosis. AML has
the highest mortality rate of all of the different types
of leukemia [2]. The French-American-British (FAB) co-
operative group identified eight different subcategories
of AML, M0-M7, based on the specific cell population
from which AML arises [3]. More recent classification
systems now exist that include other criteria besides
white cell morphology [4, 5]. Regardless, the majority of
patients with AML receive essentially identical induction
chemotherapy with drugs that target DNA replication [6].
Unfortunately, for the patients over 55 years of age diag-
nosed with AML, the 5-year survival rate is 10% and the
relapse rate is 80% [7]. Given the variability of AML pro-
gression among patients, understanding determinants of
disease progression will lead to therapeutic advances that
result in lower rates of relapse and higher rates of survival.
Computational modeling is an effective tool to person-
alize therapies for improved patient outcomes. Model-
based personalized therapy has improved several medical
interventions including: glucose control in type I diabetes
[8, 9]; automatic control of anesthesia dosage [10–12]; and
pacemaker control of heart rate variability [13]. Presently,
AML treatment is not benefiting from model-based per-
sonalized approaches, in part due to a lack of multi-
lineage AML computational models [14, 15]. Key features
of a computational model of hematopoiesis includes:
normal formation of mature cells from hematopoietic
stem cells (HSCs) [16–24]; abnormal development lead-
ing to leukemia [18, 25–27]; treatment using chemother-
apy or transplantation [17, 25, 26]; movement of cells
between the bonemarrow/tissue and the peripheral blood
where AML is frequently measured [20, 28–35]; and the
feedback signals from cytokines that participate in the
regulation of hematopoiesis [20, 25, 26, 28]. Previous
models that contain various elements of these key fea-
tures exist (summarized in Additional file 1: Table S1 in
Supplement 1). Here, we focus on the development of a
multi-lineage AML model that captures patient variabil-
ity and use the model to identify patient sub-types and
identify potential novel therapeutic targets.
In this work, we develop a semi-mechanistic multi-
lineage multi-compartment computational model of
hematopoiesis and AML. The model describes the
interactions of various lineages of hematopoietic stem
cells, including neutrophils, lymphocytes, andmonocytes.
Patient data is used to constrain the model, creating a
large number of data-consistent solutions that differ in
their responses to chemotherapy.We apply the constraints
from patient data to characterize normal hematopoiesis
versus leukemic differentiation and growth in unique
parameter sets representing 22,796 simulated patient
dynamics. To identify trends in dynamical variability, we
clustered the simulated dynamics into thirteen ‘repre-
sentative patient’ groups. We find that our mathematical
model can be used to demonstrate the typical variation in
the dynamics of AML progression and patient clinical out-
comes. Using sensitivity analysis and correlation analysis,
we identified important parameters whose variation most
affects the development of leukemia.
Methods
Herein, we develop a semi-mechanistic multi-lineage
model of leukopoiesis and the formation of AML that
includes the following: (1) variability in healthy andmalig-
nant white blood cell maturation; (2) interactions between
progenitor cells and differentiated cells; (3) interactions
amongst macrophages, neutrophils, and lymphocytes;
and (4) dynamics of hematopoiesis and AML pro-
gression (Fig. 1; model equations in Additional file 1:
Supplement 2). This ordinary differential equations
(ODE) model of hematopoiesis describes the physiolog-
ical processes of cell maturation, cell mobility between
different blood compartments in the body, interactive
responses to cytokines and the cells that produce them,
cellular activation and suppression, and cell loss due to
natural death or chemotherapy.
Model Configuration
The leukopoiesis process consists of a set of discrete stages
of cellular differentiation. There are three different stages
of cell development representing the maturation of the
stem cells into mature leukocytes (Fig. 1, solid black cir-
cles). The first stage contains the hematopoietic stem cells
(HSCs) that either asymmetrically self-renew or differ-
entiate. We assume this HSC compartment consists of
many stages of cells that have the capability to differen-
tiate into various lineages, as previous work has shown
that the dynamics of mature cells are appropriately repre-
sented in a two-compartment system [36–38]. The stem
cells proportionally differentiate into distinct progenitors,
including common lymphoid progenitors and granulo-
cyte/myeloid progenitors that then clonally amplify their
branching lineages [39]. All three lineages are necessary
to demonstrate lineage dominance and cell-cell interac-
tions amongst the three most-commonly measured white
blood cell types (see Additional file 1: Supplement 3,
Table S5 for further justification of these three lineages).
Other multi-lineage models do not consider these three
lineages [21–24]. Granulocyte/myeloid progenitors pro-
duce mature neutrophils and monocytes, which have rel-
atively short life-spans and are replaced daily. Lymphoid
progenitors branch into immature B-lymphocytes and T-
lymphocytes, yielding more complex and less predictable
Sarker et al. BMC Systems Biology  (2017) 11:78 Page 3 of 18
Bone Marrow                   Bone Marrow/Tissue
Peripheral Blood
Differentiation
Proliferation
Death Movement
Circulating Non-Circulating 
Chemotherapy
Stem 
Cell
Neut. 
Progen.
Apopto-
sis
Cancer
Lymp. 
Progen.
Mono. 
Progen.
Neutro-
phil
Lym-
phocyte
Mono-
cyte
Neutro-
phil
Mono-
cyte
Lym-
phocyte
Neutro-
phil
Mono-
cyte
Macro-
phage
Canc.
Progen. Cancer
Recruitment
Mobilization Margination
Fig. 1 Hematopoiesis model overview. Each state of the model is represented with a circle. Mature cells are colored and immature cells are shown
with black backgrounds. The compartments of the model are labeled on the top of the figure and indicated with solid colored rectangles. The
peripheral blood is divided into two compartments: circulating blood and non-circulating blood, or the marginal pool. Solid arrows represent the
differentiation from one state to the state to which the arrow points. A curved arrow indicates self-renewal capability. The group of cells that move
are boxed by a gray rounded rectangle. An ‘x’ on the bottom right of a state node represents natural death. The cells that are affected by
chemotherapy are encapsulated by the blue rounded rectangular shape. Cells that are undergoing apoptosis and will be cleared by macrophages
are in the ‘Apoptosis’ compartment
dynamics than those of myeloid cells. Thus, we focused
on studying myeloid cell production, destruction, and
deviations associated with myeloid leukemias instead of
the less predictable lymphoid leukemias. The process of
proliferation and differentiation in our model ensures a
physiological mechanism that repopulates the bone mar-
row after chemotherapy and ensures that the formation of
a single mutated cell in the HSC compartment can result
in AML.
Mature cells are maintained in three different compart-
ments: the bone marrow or tissue (yellow compartment in
Fig. 1), the circulating peripheral blood (red compartment
in Fig. 1), and the non-circulating peripheral blood, or
marginal pool (blue compartment in Fig. 1). Cells migrate
from both the bone marrow and marginal pool to the
peripheral blood and are recruited to the bone marrow
or marginal pools from the peripheral blood [40–42].
Since the concentration of normal white blood cells in the
bone marrow and peripheral blood may vary over sev-
eral orders of magnitude [40], it is essential to compute
the dynamics of the proliferation of cells within the bone
marrow and the mobilization of cells. Other multi-lineage
models do not demonstrate movement of cells amongst
compartments [21–24], and mobilization is typically lim-
ited to neutrophils or monocytes [20, 27–31, 33–35].
Additionally, neutrophils and monocytes also remain in
non-circulating peripheral blood pools, or marginal pools,
to allow for massive demargination upon a trigger event,
such as chemotherapy [40, 43].
Our final model contains 17 states that represent cell
populations and 51 parameters. The equations for this
model can be found in Additional file 1: Supplement 2,
and the model is depicted in Fig. 1. Details of these bio-
physical processes that regulate cellular dynamics are in
Additional file 1: Supplement 3. The parameter values can
be found in Additional file 1: Supplement 4. The general
form of the model for each cellular state is a sum of all of
the production terms, the movement terms, and the loss
terms (Eq. 1).
dX0
dt = +p0 ∗ X0 + s−1 ∗ X−1 − s0 ∗ X0 + m−1 ∗ Xbm/pb
− r0 ∗ X0 − d0 ∗ X0
(1)
Here, X0 is the state of interest; p0 is the proliferation
term, typically described as asymmetric self-renewal (cir-
cular arrows in Fig. 1; based on [19]; described further in
Additional file 1: Supplement 3); s−1 is the differentiation
(specialization) term from a stem cell or progenitor state,
X−1, to the state of interest, X0; s0 is the differentiation
term from the state of interest, X0, to a more mature state
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(straight solid arrows in Fig. 1);m−1 is the mobilization or
margination term from the corresponding bone marrow
or peripheral blood state, Xbm/pb, to the state of interest,
X0 (forward dashed arrows in Fig. 1); r0 is the recruitment
term of X0 to another compartment (backward dashed
arrows in Fig. 1); and d0 is the loss, or death rate (x’s
in Fig. 1). Further details of this model are described in
Additional file 1: Supplement 3. A few key physiological
details, including feedback and cell-cell interactions in the
multi-lineage model, are described below.
Feedback
Cells secrete complex cytokines and chemokines that play
a pivotal role in hematopoiesis. Cytokines regulate dif-
ferent processes that occur in the hematopoietic system,
such as self-renewal and movement [44]. Mutations in
the production or signaling of cytokines can lead to neg-
ative outcomes, such as the formation of AML [45–48].
These cytokines are not specified in our model, but are
assumed to be proportionate to the number of cytokine
releasing cells (i.e. macrophages). This is incorporated
into our model using Michaelis-Menten type kinetics to
modify the rates of cytokine-targeted processes. The gen-
eral form of negative feedback is in Eq. 2 and the general
form of positive feedback is in Eq. 3.
k
k + C rX (2)
C
k + C rX (3)
Here, k is the Michaelis-Menten constant; C is the con-
centration of the cell state that produces cytokines for
feedback; r is the rate the feedback modifies; and X is the
cell state targeted by cytokines. To model the formation
of AML from monocytes, we simulated the multiple-hit
hypothesis and assumed all feedback signals did not effect
a single normal monocyte progenitor, as expected from
literature [49].
Inhibitory feedback prevents cells from growing uncon-
trollably in any state. Thus, our model has several inhibi-
tion mechanisms to regulate the concentration of cells. In
particular, inhibition feedback modifies every rate except
cell death in our model. All movement is inhibited by
the concentration of cells in the compartment to which
cells aremoving to prevent overcrowding usingMichaelis-
Menten type kinetics (Eq. 2). Proliferation and differentia-
tion are hindered by inhibiting the associated self-renewal
probability of stem cells [19]. For progenitor cells, this
inhibition occurs from cytokines produced bymature cells
of the same lineage in the peripheral blood [50]. How-
ever, for stem cell proliferation and differentiation, this
inhibition occurs from a scaled combination of the con-
centration of stem cells to ensure that sufficient stem cells
are in the hematopoietic system and the concentration of
cells in the bone marrow (yellow compartment in Fig. 1)
do not exceed the capacity of the marrow. All negative
feedback signals are pictorially described in Additional
file 1: Figure S1. The derivation of both the form for asym-
metric self-renewal and the capacity of the bone marrow
are in Additional file 1: Supplement 3.
In contrast, several physiological processes in
hematopoiesis are triggered by positive feedback. In
response to an inflammatory event, mature white blood
cells proliferate to accommodate this response. We
include two states in our model that demonstrate the
effect of debris clearance due to chemotherapy. Mono-
cytes are recruited into the bone marrow to become
activated macrophages to help clear excessive cellular
debris [41], which we have modeled as the ‘Apoptosis’
state. Macrophages assist in recruiting other white blood
cells, such as lymphocytes, neutrophils, and monocytes,
during inflammation or other diseases [41], which we
have also incorporated into the model. Positive feedback
is used in our model to demonstrate several processes,
including inducing proliferation of macrophages by apop-
totic debris; promoting the recruitment of neutrophils,
lymphocytes, and other monocytes into the tissue in
response to high levels of macrophages; and increas-
ing the clearing rate of apoptosis due to a high level of
macrophages. All positive feedback signals are pictorially
described in Additional file 1: Figure S2. Additional file 1:
Table S4 in Supplement 2 describes each of the feedback
processes in detail.
Results
Parameter selection
The model has 51 parameters and 17 states that describe
the cell concentrations of various white blood cells and
leukemia (Fig. 1) and reflects seven qualitative and quan-
titative features found in patient responses to chemother-
apy from literature (Table 1). Seven of these param-
eters were found from literature: the death rates of
Table 1 Capabilities of multi-lineage hematopoiesis model
Healthy dynamical acceptability criteria
1. Peripheral blood recovers > 80 cells/μL [58]
2. Stem cells recover > 1 cell/μL [58]
3. Final dynamic values are within acceptable ranges (Additional file 1:
Supplement 4) [40, 59]
4. Marginal pool is within one order of magnitude of peripheral blood [43]
5. Cell counts reduce with chemotherapy to < 20% of original value [63]
6. Recovery overshoot < 12 times value five days after overshoot
[hematopoietic stem cell transplant patient data from Dr. Robert Nelson,
shown in Additional file 1: Supplement 5].
7. Amplitude of the second peak of oscillations deviates < 18% from the
amplitude of the first peak [cutoff calculated, explained in Additional file 5:
Supplement 5].
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progenitor cells [51], mature neutrophils [28, 52, 53],
mature lymphocytes in the bone marrow [54] and periph-
eral blood [25, 55], mature monocytes in the bonemarrow
[28, 56, 57] and peripheral blood [56], and macrophages
[58]. We fit the remaining 44 uncertain parameters to
reflect the seven dynamic acceptability criteria (Table 1)
of our model; these parameter values are in Additional
file 1: Supplement 4. Parameter optimization proceeded in
sequence by first identifying data-consistent parameters
in the uni-lineage models and then extending the iden-
tified parameters to the integrated multi-lineage model
(Fig. 2).
Qualitative features and properties and quantitative
patient data were used to test models and optimize param-
eters. However, given the amount of patient-to-patient
variability, this only informs regions of the parameter
space consistent with observed clinical data as opposed
to optimized parameter values. We explored for parame-
ters in a nested approach, where uni-lineage models were
evaluated independently before being combined with the
multi-lineage model (Fig. 2). Specifically, we were inter-
ested in demonstrating a realistic range of patient white
blood cell counts and the rates that dictate those counts.
Manesso et al. also used a “divide et impera" step-wise
approach to parameterizing their multi-lineage model to
demonstrate variability in [23]; however, a key difference
of their model to ours is that we searched for both initial
conditions and parameter sets that met expected steady
state configurations instead of using various parameter
set perturbations on one initial condition. In order to
find these initial conditions and parameter values, we
searched over large parameter ranges for the 44 undeter-
mined parameters using MATLAB’s lsqnonlin search
algorithm. Self-renewal fractions were bound between
0.5 and 1 to maintain stem cell mass without becoming
zero. Nominal values for the remainder of the param-
eters were approximated based on expected dynamics.
We searched between 1/5 to 5 times these nominal val-
ues to determine the bounds of the parameter space.
We simulated 100,000 Latin Hypercube samples, an effi-
cient, semi-random but uniform method of sampling,
in log space for each uni-lineage model (Fig. 3, nLHS).
Almost all of the Latin Hypercube samples produced non-
zero equilibrium solutions for further analysis (Fig. 3,
nNTEQ), but not all monocyte simulations produced equi-
librium solutions due to the stiffness of the system. In
Fig. 2 Identifying representative patients using qualitative and quantitative model features. Flowchart of the description of constraining uni-lineage
and multi-lineage parameter spaces. After setting parameters from literature, parameters specific to each uni-lineage are sampled along with the
parameters that are specific to stem cells. We characterize the simulations from these sampled parameter spaces as acceptable or unacceptable
from the dynamic acceptability criteria in Table 1 and constrain the parameter space to reflect acceptable solutions. We re-sampled the constrained
parameter space of all three lineages and simulated with the multi-lineage model. The simulations that met the acceptability criteria were used for
further analysis
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Fig. 3 Parameter space constraints for uni-lineage models using
dynamic acceptability criteria. Each circle represents the number of
simulations that met the acceptability criteria indicated by the
corresponding color-coded label. Overlapping circles demonstrate
the region in which simulations met multiple criteria. Circles with
straight edges represent an inset of the original circle and has been
scaled to show other circles more clearly. a shows the acceptability
for neutrophil uni-lineage solutions (n = 177 total acceptable),
b shows the acceptability for the lymphocyte uni-lineage solutions
(n = 1796 total acceptable), and c shows the acceptability for
monocyte uni-lineage solutions (n = 1049 total acceptable). In a and
b the parameter space constrained by the dynamical acceptability
criteria are shown as an inset to distinguish amongst the constrained
parameter sets. The two criteria that were salient in determining final
total acceptability are indicated with asterisks. The subscripts on the
‘n’s correspond to the numbered criteria from Table 1
order to determine the parameter ranges that met the
dynamical criteria from Table 1 (further detailed in the
following section), we simulated chemotherapy for 7 days
on each of the non-trivial equilibrium solutions (details of
chemotherapy in Additional file 1: Supplement 3). Accept-
able solutions met all seven of the dynamical acceptability
criteria (nF = 177 for neutrophils, nF = 1796 for lympho-
cytes, and nF = 1049 for monocytes). Figure 2 depicts the
process, and Fig. 3 shows the intersection of all acceptable
parameter regions.
Physiological capabilities of model
Data-consistent simulations not only fit the patient data,
but they also meet a number of qualitative and quantita-
tive criteria (summarized in Table 1). These seven capa-
bilities were mostly determined from literature, though
we also used data from Dr. Robert Nelson of the Indi-
ana University Simon Cancer Center from patients who
received hematopoietic stem cell transplants (HSCT) to
determine additional empirical evidence of the patient
dynamics (IRB Protocol# 1011009928). Further informa-
tion on the patient data is included in Additional file 1:
Supplement 5. The patient data was used to determine
cell concentration bounds, but were not used to validate
the time course of patient recovery after transplantation.
Thus, a donor infusion was not modeled. The pharma-
cokinetics and pharmacodynamics of chemotherapy was
simulated as described in Additional file 1: Supplement 3,
and was implemented as a ‘chemo’ term in the model
equations (Additional file 1: Supplement 2). The details of
these criteria are below.
1. Peripheral blood recovers > 80 cells/μL: This
ensures that the peripheral blood sufficiently
recovers after chemotherapy treatment, and the
final peripheral blood cell count must be >
80 cells/μL [58].
2. Stem cells recovery > 1 cell/μL: The final stem cell
concentration must be between 1 and 100 cells/μL. If
the stem cell concentration is within the acceptable
bounds, the stem cells should also show recovery
after chemotherapy occurring [58].
3. Final dynamic values are within acceptable
ranges: The final uni-lineage peripheral blood cell
counts after chemotherapy must be within the upper
limits of expected normal peripheral blood cell
counts [40, 59]. Neutropenia (low number of
neutrophils in the peripheral blood) is very common
after undergoing chemotherapy [60], but
neutrophilia mostly occurs if another underlying
disease exists to cause the high number of
neutrophils. We do not want to model neutrophilia
during recovery from chemotherapy because that is
not a typical response in patients with AML. The
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values each cell state must be within are depicted in
Additional file 1: Supplement 4, Table S6.
4. Marginal pool is within one order of magnitude
of peripheral blood: The final concentration of the
cells in the marginal pool must be within one order
of magnitude of the final concentration of the
peripheral blood because the size of the marginal
pool and peripheral blood compartments are
approximately the same [43, 61, 62]. Though a
marginal pool can exist for lymphocytes, it is much
smaller than that of neutrophils and monocytes [43].
Thus, we do not incorporate a lymphocyte marginal
pool in our model.
5. Cell counts reduce with chemotherapy to < 20%
of original value: The concentration of cells
remaining at the end of chemotherapy should be less
than 20% of the concentration of cells before
chemotherapy begins [63].
6. Recovery overshoot < 12 times value five days
after overshoot: Patients experience lymphopenia,
or low white blood cell concentrations, during
chemotherapy. After the chemotherapy regimen is
completed, patients’ cell counts almost always
increase. In some instances, patient cell counts
increase and peak above their final homeostatic cell
concentration. Here, we define this overshoot level as
the maximum concentration of cells after
chemotherapy administration is completed. If the
overshoot level is more than twelve times the
concentration of cells five days after the overshoot
(or the concentration of cells at the end of the
simulation, whichever comes first), the solution is
rejected. This overshoot was the maximum observed
in the HSCT patient data from the Simon Cancer
Center (Additional file 1: Figure S6 in Supplement 5).
7. Amplitude of the second peak of oscillations
deviates < 18% from the amplitude of the first
peak: Several simulations produced oscillations.
Though some small oscillations are reasonable and
can occur physiologically, large oscillations are
unlikely because they will not maintain normal
homeostasis in the body and most patients who are
treated for AML do not report large oscillations in
cell counts. We manually classified 100 simulations
for sufficiently dampened oscillations. We calculated
that a simulation was sufficiently dampened if the
cell concentration of the second peak value
post-chemotherapy was less than an 18% decrease
from the first peak post-chemotherapy. Thus, we
implemented this cutoff for all of our simulations. An
example of a simulation that does not meet this
criteria and a simulation that does meet this criteria
are shown in Additional file 1: Figure S7 in
Supplement 5.
For each uni-lineage parameter search, two criteria were
salient in determining which models met the physiologi-
cal features required based on responses to chemotherapy.
The remainder of the criteria are mostly robust in con-
straining the parameter space. One of the salient criteria
was the lack of oscillations for each uni-lineage model.
This implies that the need to maintain a steady-state con-
centration of cells for each of the lineages independently is
one of the key constraints in normal hematopoiesis and is
consistent with parameters that lead to balanced feedback.
The second criteria that largely determined the accept-
able uni-lineage models were the final peripheral blood
acceptable dynamics of the neutrophil uni-lineage model,
stem cell recovery for the lymphocyte uni-lineage model,
and sufficient response to chemotherapy for themonocyte
uni-lineage model (indicated with asterisks in Fig. 3). This
reflects the necessity of maintaining high concentrations
of neutrophils in homeostasis and the ability of cells to
repopulate cell populations for appropriate recovery. If we
relaxed the constraints imposed on the model set by the
features of normal physiological dynamics, the acceptable
parameter sets would be larger as well.
Parameter constraints with separatrix method
We identified several relationships among pairs of uncer-
tain parameters in the models that met the dynamic capa-
bilities of uni-lineage models. This demonstrates param-
eter relationships that maintain the normal physiological
responses to stimuli, and reveals certain physiological pro-
cesses that are directly related in a specific manner to
each other. We discovered that negative exponential rela-
tionships exist between pairs of parameters, especially
between the fraction of cells that self-renew and the mito-
sis rates of cells (Fig. 4). This implies that either themitosis
rate or the probability of cell renewal needs to be high
for a progenitor cell to sustain its population. If both of
these rates are high, however, instability occurs. Tradi-
tional methods of separating data in multiple dimensions
into groups do not define the bounds of the groups, such
as in clustering [64], or do not separate multiple linear
separations observed in Fig. 4, such as in support vec-
tor machines [65]. A computationally efficient method of
separating multiple linear constraints is needed. Thus, to
constrain the parameter space based on these relation-
ships, we developed a separatrix method that defined the
bounds of the relationships between parameters.
The separatrix method distinguishes between parame-
ter regions of acceptable solutions and regions of unac-
ceptable solutions, and in log-space, this manifests as
a clear separatrix. We first constrain to the acceptable
range of each parameter (dashed black box in Fig. 4).
For each unique pair of uni-lineage parameters, we then
divide the parameter range rectangle into 10 × 10 equally
sized bins. If the acceptable parameter set is uniformly
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Fig. 4 Uni-lineage pair-wise parameter constraints with separatrix method. Five pair-wise parameter relationships from the unilineage models
emerged between self-renewal probability and mitosis rate (a-c, e) and the michaelis-menten constant for neutrophils (d). For all subfigures, the
legend is the same. Gray dots that cover the majority of the background represent all equilibrium solutions that were sampled, but did not meet the
final acceptable dynamic values and were zero-equilibrium solutions. Solutions that did not meet the other acceptability criteria are shown with red
‘x’s. Blue triangles represent acceptable parameter sets. We defined a separatrix, which is outlined with a dashed black box that represents the limits
of the range of the acceptable parameter space. The dashed green lines show the corners of the separatrix that were removed
distributed in parameter space, every bin has a cut-
off of (number of acceptable simulations)/100 acceptable
parameter sets. Thus, each of the 100 bins is either accept-
able or unacceptable depending on whether more accept-
able parameter sets existed in the bin than the cutoff value.
We then further constrain this acceptable parameter den-
sity by removing corners of the range rectangle that did
not maintain a cutoff density of acceptable parameter sets
(dashed green lines in Fig. 4). Thus, we found a set of
inequalities for each unique pair of parameter sets in the
uni-lineage parameterization in log space. We used this
separatrix constraint on the parameter search space for
multi-lineage parameterization.
The separatrices of each pair-wise parameter rela-
tionship confirm parameter relationships from previous
works, and we identified additional required relation-
ships in the acceptable solutions. As Getto et al. [38] and
Stiehl et al. [52] show, the mitosis rate of stem cells and
the probability of self-renewal are inversely related. How-
ever, we found that this also extends to all progenitor
cells (Fig. 4a-c). Specifically, a linear relationship emerges
between the log of the self-renewal probability and the log
of the mitosis rate. Solutions that have larger mitosis rate
or self-renewal probabilities produce oscillations (red x’s
in Fig. 4), which we constrained against in our dynami-
cal acceptability criteria (Criteria 7 in Table 1). We also
found a similar inverse linear relationship between the log
of the self-renewal probability of neutrophil progenitors
and the log of the homeostatic constant of neutrophils
in the peripheral blood; solutions that have lower values
of either of these two parameters becomes unaccept-
able (Fig. 4d). Overall, this finding means that a specific
relationship is maintained between the probability of self-
renewal and the mitosis rate for all cells that are capa-
ble of self-renewing to ensure that the cell population
remains steady. Additionally, due to the high concentra-
tion of neutrophils, a constrained feedback mechanism
exists between the self-renewal probability of neutrophil
progenitors and the cytokines produced by neutrophils in
the peripheral blood to maintain appropriate homeostatic
concentrations of those cells. Overall, we confirmed the
dependence on the mitosis rate and self-renewal probabil-
ity of stem cells found by other groups (Fig. 4e), but we
also found additional dependencies on these same param-
eters of progenitor cells, as well as a specific dependence
of the cytokines produced by neutrophils in the peripheral
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blood and the self-renewal probability of neutrophil pro-
genitor cells.
Multi-lineage acceptable solutions
Following analysis of uni-lineage models, we integrated
the uni-lineage models into a single multi-lineage model
of leukopoiesis and AML to identify the constraints
on the rates that regulate normal hematopoietic and
leukemic proliferation. To evaluate model performance,
we required the complete model to be consistent with
all of the constraint data that informed the uni-lineage
models. We used the specific parameter relationships
gleaned from using separatrices on the uni-lineage mod-
els to select a set of models that meet the capabilities
of the uni-lineage models. Thus, we simulated 100,000
Latin Hypercube samples of the 44 undetermined param-
eters in the constrained multi-lineage parameter space
(Fig. 5, nLHS). 40,368 parameter sets maintained home-
ostasis (Fig. 5, nNTEQ); of which, 22,796 simulations with
specific parameter sets and initial homeostatic conditions
were deemed acceptable simulations using the same seven
dynamic criteria from Table 1 (intersection of accept-
able parameter spaces in Fig. 5, nF ). The lymphocyte
uni-lineagemodels caused themost constraints on the full
multi-lineage models, specifically to restrict the oscilla-
tions and promote recovery post-chemotherapy in lym-
phocytes (Fig. 5). This is potentially due to the large
concentration of lymphocytes and their rapid selection
in the thymus [54] in contrast to their long half-lives in
the peripheral blood [25, 55]. Overall, in the final multi-
lineage model, the acceptable parameter sets represent
22,796 virtual healthy patients. All of the mean and ranges
of the parameters that were varied are in Additional
file 1: Supplement 4, Table S8. Correlation coefficients of
the initial conditions and parameter values of the multi-
lineage model are shown in Additional file 1: Figure S5 in
Supplement 4.
A comparison of the simulations of the multi-lineage
solutions to the simulations of the uni-lineage solutions
is shown in Fig. 6a-d. In the stem cell and all peripheral
blood cell compartments, the uni-lineage models allow
for a greater spread of cell dynamics than in the multi-
lineage models. Specifically, the overshoot of recovery
of cells post-chemotherapy is dampened in the multi-
lineage solutions. This means that the combined feedback
from cytokines from different lineages has a stabilizing
effect. Additionally, in observing the distributions of the
concentration of cells of the multi-lineage solutions in
comparison to the uni-lineage solutions at specific time
points (Fig. 6e-h), the multi-lineage solutions (blue lines
in Fig. 6e-h) have lower cell concentrations at the early
time points (dotted and dashed lines in Fig. 6e-h) but
higher cell concentrations at later time points near home-
ostasis (solid lines in Fig. 6e-h). This implies that in
order to maintain acceptable cell dynamics in a multi-
lineage system, the concentration of cells needs to be at a
higher homeostatic concentration than if only considering
the uni-lineage model. The overshoot of the lineages in
Fig. 6a-d are all well within patient variation (Additional
file 1: Figure S6 in Supplement 5); though, our simu-
lation dynamics may be too constrained in comparison
to patient data. Forty out of the 47 patients (85%) in
Additional file 1: Figure S6 do not demonstrate neu-
trophil overshoot, but none of our multi-lineage neu-
trophil simulations demonstrate this overshoot. We find
that constraining the uni-lineage models to multi-lineage
data may have constrained the multi-lineage model more
than patient overshoot data reflects. We additionally test
LHS Solutions
(nLHS = 100,000)
Equilibrium Solutions
(nEQ = 95,949)
Stem Cell Recovery
(n2 = 39,413)
Non-Trivial Equilibrium
(nNTEQ = 40,368)
Lymphocyte Chemotherapy Response*
(n5,L = 26,759)
Monocyte Chemotherapy Response
(n5,M = 40,328)
Lymphocyte No Oscillations*
(n7,L = 37,217)
Acceptable Solutions
(nF = 22,796)
Fig. 5 Parameter space constraints for multi-lineage HSC models using dynamic acceptability criteria. Each circle represents the number of
simulations that met the acceptability criteria indicated by the corresponding color-coded label. Overlapping circles demonstrate the region in
which simulations met multiple criteria
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Fig. 6 Uni-lineage and multi-lineage simulations comparison. The effects of constraining the uni-lineage parameter space for multi-lineage
simulations are shown in (a) stem cells, (b) neutrophils in the peripheral blood, (c) lymphocytes in the peripheral blood, and (d) monocytes in the
peripheral blood. The distribution of solution concentrations of these cells at three different time points, indicated by red lines in (a-d), of both
multi-lineage and uni-lineage are shown for the same respective states in (e-h). The time points were chosen to demonstrate the distributions as
cell concentrations are recovering from chemotherapy, at the peak of recovery, and homeostasis post-chemotherapy. The uni-lineage acceptable
simulations are shown in green and the multi-lineage acceptable simulations are shown in blue in the front of the image. For the distributions of the
simulations, the dotted lines are a dark shade of blue or green and represent the earliest time point, the dashed lines represent a time point around
the peak of response, and the solid brightest line represents a steady-state time point. The uni-lineage simulations of stem cells are from the
lymphocyte uni-lineage. The distributions were scaled such that the area under each curve is 1
the robustness of the multiple lineages in the model by
perturbing progenitor neutrophils and testing the dynam-
ics before reaching homeostasis on the different lineages
when coupled together compared to when decoupled.
We found that the multi-lineage model tempers the
effects of this perturbation in the neutrophil lineage but
causes lymphocyte dynamics to change (Additional file 1:
Supplement 6, Figure S8).
Sensitivity analysis reveals importance of self-renewal
probability and cytokines
We carried out a sensitivity analysis on the multi-lineage
solutions to determine the most important parameters
whose variation most greatly affected output. Using a par-
tial rank correlation coefficient (PRCC) method [66–68],
we determined the parameters that were most impactful
in determining concentrations of stem cells, neutrophils
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in the peripheral blood, lymphocytes in the peripheral
blood, and monocytes in the peripheral blood. We found
that, in general, the probability of self-renewal and the
Michaelis-Menten constant that modifies both the rate
of self-renewal probability and the movement of mature
cells into the peripheral blood were the most important
parameters for their respective cell states. This indicates
that the probability of a cell to self-renew is very sensi-
tive to changes in the system and can cause very drastic
outcomes in the final cell concentration if this rate is
affected, which corroborates with findings in Marciniak-
Czochra et al. [19]. Additionally, for stem cells, the feed-
back cytokines from the concentration of cells in the
bone marrow and the concentration of stem cells were
very important parameters. These constants also modify
the probability of self-renewal in the stem cells. Finally,
many parameters that are associated with neutrophil
homeostasis (self-renewal probability of neutrophil pro-
genitors, mitosis rate, Michaelis-Menten constant, and
mobilization rate) all were very important in the stem
cell concentration. This is probably due to the large con-
centration of neutrophils affecting the homeostasis values
of stem cells. The PRCC results are in Additional file 1:
Supplement 6.
Representative patient clusters
In order to simulate cancer in a feasible number of
patients, we clustered the 22,796 solutions in the normal-
ized dynamic space. This means that we normalized each
state in each parameter set simulation by the maximum
value simulated. We clustered these normalized simula-
tions across all states and 162 time points (daily from
day -7 to day 150 and once every subsequent 30 days
until day 300) using k-means, where chemotherapy was
applied from day -7 to day 1. We found that 13 clus-
ters maximized the dynamical similarities within a cluster
over all states and minimized the overlap in the dynam-
ics across all states between clusters. These 13 clusters
represent 13 sub-groups of patients, and the centroid of
each of these clusters is the most representative patient
for each cluster. For more information on determining the
number of clusters, see Additional file 1: Supplement 7.
In Fig. 7a and b, we show how the dynamics are clus-
tered across some of the most varied dynamical regions
from Fig. 6. Stem cells group into two distinct behav-
iors; stem cell concentrations reach homeostasis within
two months post-chemotherapy for all but three clus-
ters (Fig. 7c). Normalized neutrophil dynamics are fairly
constrained, and the majority of its variation occurs dur-
ing the rapid recovery of neutrophils post-chemotherapy
(Fig. 7d). However, the overall dynamics of the normal-
ized clustered representatives demonstrate the variability
in both lymphocytic (Fig. 7e) and monocytic dynam-
ics (Fig. 7f). In general, the various clusters differ from
each other primarily by the normalized monocyte con-
centration in the peripheral blood post-chemotherapy,
overshoot in the concentration of lymphocytes in the
peripheral blood, recovery time of neutrophils in the
peripheral blood, and the homeostatic concentration of
stem cells relative to their initial concentration post-
chemotherapy. A correlation analysis did not reflect any
significant differences in the independent parameter val-
ues amongst the thirteen clusters. However, simulations
within individual clusters may have parameter dependen-
cies that are different between clusters. Real patients can
potentially be assigned to clusters based on their dynam-
ics following one round of chemotherapy, though outlier
patients need to be sufficiently explored to encompass
true patient dynamics.
Modeling leukemia
AML is a derivative of common granulocyte macrophage
progenitor cells [3, 69]. Thus, leukemia is modeled paral-
lel to the manner in which monocytes are modeled. We
assume that the cancer stem cells self-renew and prolifer-
ate at the same rate as monocytic progenitor cells. These
then differentiate intomature cancer within the bonemar-
row, which can mobilize into the peripheral blood. The
only difference in the model between leukemic stem cells
and monocytes is that the leukemic cells do not maintain
homeostasis, so all feedback that regulates self-renewal
[18, 70], differentiation, andmovement were removed and
the cancer cells cannot be recruited back to the tissue.
Since we have modeled feedback from various signals, the
mutated cancer cell that grows indefinitely is the prod-
uct of several mutations that cause all feedback to be
inhibited, as currently hypothesized in literature [49].
We simulated AML with one cancer stem cell, and
allowed the leukemia to clonally accumulate in each of
the 22,796 simulated patients (Fig. 8a), as expected from
literature [71]. The variation shows that some patients
may survive only a few months after the cancer starts
(i.e., pink cluster lines in Fig. 8a; gray lines indicate death)
and some patients may live close to one year without
any other intervention (i.e., green cluster lines in Fig. 8a).
In order to determine how long patients in each cluster
would live without any treatment, we assumed patients
would survive until the concentration of cancer cells in
either the peripheral blood or bone marrow was greater
than 3 × 105 cells/μL (Fig. 8a-d). This is the theoreti-
cal maximal concentration of cells in the bone marrow
calculated in Additional file 1: Supplement 3, given the
diameter of monocytes and assuming the volume in the
bonemarrow and peripheral blood are the same. Figure 8b
shows the AML growth as a percentage of the periph-
eral blood. AML is diagnosed when over 20% of the bone
marrow or peripheral blood contains cancer blasts, or
immature cancer cells [72], and our model indicates that
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Fig. 7 Representative parameter sets. The 22,796 parameter set dynamics of (a) normalized stem cell concentration at 30 days after the start of
chemotherapy (x-axis) versus the normalized monocyte concentration in the peripheral blood at 42 days after the start of chemotherapy and
(b) normalized neutrophil concentration in the peripheral blood at 18 days after the start of chemotherapy (x-axis) versus the normalized
lymphocyte concentration in the peripheral blood at 30 days after the start of chemotherapy are shown with ‘*’, color-coded according to cluster.
The time points plotted were chosen to demonstrate the clustering at times of maximum variation in the dynamics of the particular cell states. The
thirteen clusters are each represented with distinct colors, and the centroids of each cluster are shown with a black-outlined circle. To demonstrate
the differences in the dynamics of the representatives, the response of (c) stem cells, (d) neutrophils in the peripheral blood, (e) lymphocytes in the
peripheral blood, and (f) monocytes in the peripheral blood to chemotherapy from day -7 to day 0 are shown normalized to the maximum value of
each simulation. Again, each distinct color represents a different cluster centroid, or representative patient, and these colors correspond to the same
clusters as in Figures 7a and b
patients can remain undiagnosed with AML for weeks
to months, as previously suggested [73]. The growth of
AML is simulated to stop when the theoretical maxi-
mum concentration of bone marrow cells is reached. In
Fig. 8b, patients with slower growing cancers die with
AML comprising a higher percentage of their periph-
eral blood. Figs. 8c-d indicate that patients within some
clusters have a much better prognosis than others, and
generally correlates with a slower recovery of monocytes
post-chemotherapy (corresponding colors in Fig. 7e).
For a simple validation to ensure that cancer is not
growing too slowly in our model, we can compare overall
survival times of the simulations without treatments to
trials in which patients received low-dose treatments. The
majority of clinical patients who are unable to receive
traditional chemotherapy and received hydroxyurea as a
treatment post-diagnosis with AML died within one year
of diagnosis even with favorable stratification [74]. We
find the survival time in all of our simulations to be less
than four months in after diagnosis of AML > 20% blasts
(Fig. 8b). Thus, cancer growth fits within an expected
bound of patient survival.
To test which parameters correlate with the survival
time of patients with AML, we correlated survival time
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Fig. 8 Survival in leukopoiesis. Each of the thirteen clusters is represented with a distinct color in a-d, corresponding to the same colors as in Fig. 7.
(a) Progenitor cancer stem cells (Mc2) grow over one year in each of the 22,796 simulations. The gray lines represents the cell concentration and time
in which patients may die due to overgrowth of cancer cells. (b) The percentage of cells in the peripheral blood due to AML in each of the 22,796
simulations. Patients die prior to reaching 100% peripheral blasts, as indicated by gray lines where simulation continued. In (a) and (b), some cluster
simulations are not visible because they are underneath the other simulations. (c) The simulated survival curves of each of the thirteen representative
clusters of patients are shown assuming the patient dies when either cancer in the bone marrow or the peripheral blood reaches a concentration
greater than 3 × 105 cells/μL. The cumulative survival is shown as a decimal that represents the fraction of patients that are still alive at the time
shown on the x-axis.(d) The distribution of the time to death for each cluster is indicated using box plots. Medians of the distribution are shown as
red horizontal bars and outliers are shown as red plus signs (+). (e) Significant cancer parameter correlation to number of days until death due to
bone marrow or peripheral blood density greater than 3×105 (p < 0.05). (f) Significant cancer parameter correlation constrained with a fixed cancer
mitosis rate to the number of days until death due to bone marrow density or peripheral blood density greater than 3 × 105 (p < 0.05). In figures
(e) and (f), gray boxes represent insignificant correlations, and the correlation values for each of the thirteen clusters are depicted with the color bar
to the four parameters that mediate cancer in our model:
(1) the death rate of all cancer cells (dMc), (2) the frac-
tion of cells that self-renew (aMc2), (3) the mitosis rate
of cancer progenitor cells (mrMc2), and (4) the mobiliza-
tion of cancer cells into the peripheral blood (mbMc).
For the 22,796 cancer simulations, these parameter val-
ues were assumed to be the same as those of monocytes
in healthy hematopoiesis. In order to determine which of
the parameters that determine survival time the most, we
sampled 625 Latin Hypercube Samples for each of the 13
representative patients. For this sampling, we varied the
parameters, dMc, aMc2, mrMc2, and mbMc within the
ranges shown in Table 2. These bounds were chosen to
ensure the death and mobilization rates were slower than
those of normal monocytes, but mitosis rates are higher.
We computed a correlation of all of the diagnosed cancers
in these simulations (bone marrow or peripheral blood
blast concentration > 20% and cancer stem cell concen-
tration > 1 cell/μL) to the number of days of survival.
We found that across all clusters, the mitosis rate of can-
cer was correlated with survival without chemotherapy.
The overall negative correlation of -0.7431 (Fig. 8e) indi-
cates that the higher the mitosis rate, the more likely the
patient will die earlier without treatment. We constrained
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Table 2 Cancer parameter bounds
Parameter Lower bound Upper bound
dMc 0.0001dM dM
aMc2 0.01aM2 1
mrMc2 0.5mrM2 30
mbMc 0.0001mbM mbM
Four parameters were varied for determining the most correlated cancer parameter
to survival time: the death rate of cancer (dMc), the self-renewal probability of cancer
progenitor cells (aMc2), the mitosis rate of cancer progenitor cells (mrMc2), and the
mobilization rate of cancer stem cells (mbMc). The bounds of these parameters were
restricted based on the corresponding parameters of monocytes
this same search by fixing the mitosis rate. and found that
the next most correlated parameter to survival time was
the probability of self-renewal of cancer, with an over-
all correlation of -0.8774 (Fig. 8f). This result aligns with
the inverse relationship found between mitosis rates and
self-renewal probability (Fig. 4). Stiehl et al. have similarly
found that high proliferation rates and high self-renewal
rates can also lead to earlier death [52]. We simulated
AML derived from neutrophil progenitors analogously to
simulating monocytic AML and confirmed these results
(Additional file 1: Supplement 8).
Discussion
When a patient is diagnosed with AML, physicians assess
the white blood cell counts of the patient to guide the
course of action for treating the leukemia. Many patients
are successfully treated with a stem cell or bone mar-
row transplant from a matched donor. However, for
those patients who are unable to receive a transplant,
chemotherapy is administered periodically to lower the
cancer load on the patient. Generally, a high white blood
cell count makes the patient a candidate for chemother-
apy. However, it is likely that factors other than the abso-
lute cell count are important for determining a patient’s
prognosis. Using a multi-lineage model of the formation
of white blood cells, we find that (1) certain physiologi-
cal rate relationships are necessary to prevent unstable cell
population growth and (2) the rate of growth of the can-
cer is an important prognostic factor in determining the
survival time of patients.
We determined that there are specific physiological
rates and cell concentrations that are crucial in maintain-
ing homeostasis. As expected, progenitor cells are very
important in homeostatic mechanisms. A sensitivity anal-
ysis demonstrated that the probability of self-renewal of
all progenitor cells and parameters that modify this proba-
bility are the most important parameters in hematopoietic
dynamics. Other groups have found similar results [19]
in the context cancer [75, 76] and specifically AML [77].
Additionally, we found an inverse relationship between
the self-renewal probability of stem cells and the mitosis
rate of stem cells (Fig. 4e), corroborating findings of other
groups [38, 52]. This relationship between mitosis rate
and self-renewal probability also exists for progenitor
cells (Fig. 4a-c), which was not found previously. In gen-
eral, solutions that have high mitosis rates or self-renewal
probabilities lead to oscillations in the cell concentrations.
This oscillation is highly undesirable and can occur in
diseases such as cyclic neutropenia. Previous work has
shown that “re-entry" into the stem cell compartment was
found to be one of the factors that control oscillation
in cyclic neutropenia [22]. Our work suggests that the
analogous self-renewal probability and mitosis rate of the
same cell, whether it is the stem cell or another progen-
itor cell, are both crucial to control to prevent diseases
such as cyclic neutropenia. Chemotherapy that targets
only one of these rates may not be sufficient in controlling
physiological oscillations. Thus, we recommend that the
feedback mechanisms that govern the self-renewal proba-
bilities are explored as potential pharmaceutical targets in
AML treatment.
We found that peripheral blood concentration levels
of neutrophils and lymphocytes are important factors in
maintaining homeostasis in our model (Fig. 6), specifi-
cally in the multi-lineage context. This was evidenced in
three ways. First, when we identified the capabilities of our
multi-lineage model, we found that lymphocyte dynamics
constrained the range of acceptable solutions for all three
lineages (Fig. 5). This is likely due to the high selection
rate of lymphocytes in the thymus (dL3, which is mod-
eled as the tissue/bone marrow compartment) [54] and
low death rate of lymphocytes in the peripheral blood
(dL3pb) [25]; this can lead to fast dynamic changes if not
constrained appropriately. Second, the inverse relation-
ship between the self-renewal probability of neutrophil
progenitors and the homeostatic term for neutrophil pro-
genitors is a novel relationship in hematopoietic modeling
that tightly regulates healthy neutrophil behavior (Fig. 4d).
This means that in order to maintain healthy levels of neu-
trophils at homeostasis, either the fraction of neutrophil
progenitor cells that self-renew has to be low or the feed-
back mechanism that maintains neutrophil homeostasis
has to have a low threshold for turning self-renewal off.
Thus, self-renewal is very tightly regulated to ensure that
cells do not grow indefinitely. To reduce the cancer load
for potential treatment, physicians could target the feed-
back mechanisms associated with self renewal probability,
in particular focusing on cytokine signaling. Third, the
large concentration of neutrophils cause the parameters
associated with neutrophils to be important parameters
in determining the concentration of stem cells, as deter-
mined by global sensitivity analysis. We confirmed the
importance of neutrophils in relation to lymphocytes in
the multi-lineage model by testing the robustness of the
multi-lineage model in Additional file 1: Supplement 6.
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We also found that the neutrophils in our multi-lineage
model might be over-constrained by comparing to clinical
overshoot data in comparison to the uni-lineage models.
Specifically, the neutrophil overshoot of the multi-lineage
model only reflected the neutrophil overshoot in 85% of
clinical data (Additional file 1: Figure S6 in Supplement 5).
Thus, ourmodel encompassesmost of the dynamics of the
patient population. Furthermore, this reflects the impor-
tance of the sensing mechanism of each of these cells
to maintain appropriate homeostatic levels. When we
modeled cancer, removing these homeostatic terms from
our model allowed the cancer to grow indefinitely, as
expected. Thus, treatment that targets the feedback recep-
tors on cancer cells can drastically help reduce the cancer
load.
Individual patients are likely to develop unique phe-
notypes of AML. The dynamics and relative ratios of
the absolute concentrations of neutrophils, lymphocytes,
and monocytes vary widely across the patient popula-
tion. Furthermore, phenotypic variability of leukemia may
depend on the specific source cell within the population of
common granulocyte progenitors that first becomes can-
cerous. Here, we develop a mathematical model that is
able to describe patient variability in AML. We find that
though cancer will form when homeostatic mechanisms
are altered, additional mutations that increase the mito-
sis rate of cancer will reduce the survival of the patient
without intervention (Fig. 8e). Current chemotherapy reg-
imens inhibit DNA replication, which corresponds to
inhibiting the mitosis rate of the cancer [78]. However,
we also find that if the mechanism that determines the
probability of self-renewal of cancer cells is mutated, then
this can be an additional target for pharmaceutical treat-
ments (Fig. 8f), similar to what has been found in other
work [75, 77].
The multi-lineage model developed in this work
can be modified to explore mechanisms governing
hematopoiesis and leukopoiesis. For example, the model
could be adapted to discriminate amongst chemotherapy
regimens on simulated patients to identify characteris-
tics of patients that would benefit from certain regimens.
Then, this could lead to identification of treatment sched-
ules optimized for individual patients. The patient clusters
could be used to stratify real patients by using the dynam-
ics of patients’ responses to chemotherapy to match to
a specific simulation and its outcome. Additionally, since
we found that the probability of self-renewal is a poten-
tial secondary target for chemotherapy, various specific
feedback mechanisms could be incorporated to identify
the exact cytokine signal that would be the best target
for therapy. This could be further used to identify the
feedback signals that are most sensitive to cause AML
growth. Furthermore, the linear relationship in log-log
space between mitosis rates and self-renewal probabilities
that was found in our model could be tested experimen-
tally to ensure these relationships exist, though mediating
cytokines properly is very difficult. Though we did not
find specific relationships amongst the different lineages,
the signaling mechanisms that control bone marrow size
could also be explored experimentally and compared with
the model to regulate overproduction of a particular cell
lineage with respect to other lineages. Specifically, GM-
CSF is often used to regulate the stem cell production of
neutrophils and macrophages [79]. This could be manip-
ulated to identify effects in lymphocyte counts and the
production of AML. Overall, the multi-lineage model
we present here can be extended to characterize many
aspects of hematopoiesis.
The multi-lineage model of hematopoiesis and
leukopoiesis developed in this work can be readily adapted
and expanded to incorporate many other immunolog-
ical effects. Various groups have already modeled bone
marrow transplantation and its potential complications
[31, 33, 34]. Using our model, bone marrow or stem cell
transplantation and transplant rejection can be integrated
to predict graft rejection, and different lymphocyte sub-
types can be added to the model, such as natural killer
cells, to model an alternative outcome of transplantation:
graft versus host disease. Lymphocytic leukemias can
be explored by altering the homeostatic mechanisms of
lymphocytes; analogously, myelodysplastic syndromes
and minimal residual disease could be further charac-
terized by determining parameter changes that lead to
appropriate model behavior. Additionally, a wide array of
other immunological diseases or the wide array of patient
responses (including a large T-cell repertoire) can be
adapted into this multi-lineage model to characterize the
complexity of normal function and other immunological
diseases. More specifically, future work could character-
ize the mechanisms that cause spontaneous remission of
AML in the presence of bacterial infection [80].
Conclusions
The multi-lineage mathematical model we have created
of hematopoiesis and leukopoiesis can help identify how
individuals differ in their white blood cell and leukemia
production. This model is useful for several reasons. We
have determined crucial parameters and parameter rela-
tionships that can be used as potential drug targets for
both AML and other potential immunological disorders.
For many chemotherapeutic drugs, DNA replication is
targeted [78], which aligns with targeting the mitosis rate.
However, a combination therapy that also addresses the
probability of a cancer cell to self-renew could be poten-
tially helpful for patients whose cancer becomes resistant
to the initial therapy. There is no current way to experi-
mentally determine how these different lineages interact
and limit each other. Thus, this multi-lineage model is
Sarker et al. BMC Systems Biology  (2017) 11:78 Page 16 of 18
a very powerful tool that can aid in understanding how
blood forms normally and misforms into AML in indi-
vidual patients. In addition, the model captures multiple
dynamics that represent specific patient subgroups. By
clustering the wide population of individual differences,
we find that one advantage of this multi-lineage model
is that it can be readily extended to investigate person-
alization of treatment schedules of individual patients to
prolong overall survival.
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